The decrease of expression of ryanodine receptor sub-type 2 is reversed by gentamycin sulphate in vascular myocytes from mdx mice

Jean-Luc Morel a, *, Fabrice Dabertrand a, Nicolas Fritz b, Morgana Henaff a, Jean Mironneau a, Nathalie Macrez a

a Université de Bordeaux, CNRS, Centre Neurosciences Intégratives et Cognitives, Unité Mixte de Recherche, Talence Cedex, France
b Molecular Neurobiology, Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

Received: October 25, 2008; Accepted: January 21, 2009

Abstract

The mdx mouse, a model of the human Duchenne muscular dystrophy, displays impaired contractile function in skeletal, cardiac and smooth muscles. We explored the possibility that ryanodine receptor (RYR) expression could be altered in vascular muscle. The three RYR sub-types were expressed in portal vein myocytes. As observed through mRNA and protein levels, RYR2 expression was strongly decreased in mdx myocytes, whereas RYR3 and RYR1 expression were unaltered. The use of antisense oligonucleotide directed against RYR sub-types indicated that caffeine-induced Ca^{2+} response and Ca^{2+} spark frequency depended on RYR2 and RYR1. In mdx mice, caffeine-induced Ca^{2+} responses were decreased in both amplitude and maximal rate of rise, and the frequency of Ca^{2+} sparks was also strongly decreased. The gentamycin treatment was able to increase both the expression of RYR2 and the caffeine-induced Ca^{2+} response to the same level as that observed in wild-type mice. Taken together, these results confirm that RYR1 and RYR2 are required for vascular Ca^{2+} signalling and indicate that inhibition of RYR2 expression may account for the decreased Ca^{2+} release from the SR in mdx vascular myocytes. Finally, we suggest that gentamycin can restore the Ca^{2+} signalling in smooth muscle from mdx mice by increasing RYR2 and dystrophin expression. These results may help explain the reduced efficacy of contraction in vascular myocytes of mdx mice and Duchenne muscular dystrophy–afflicted patients. Gentamycin treatment could be a good therapeutic tool to restore the vascular function.

Keywords: ryanodine receptor • calcium signalling • muscular dystrophy • mdx • gentamycin • smooth muscle • vascular myocyte

Introduction

Dystrophin is a cytoskeletal structural protein normally expressed in skeletal, cardiac and smooth muscles [1]. The absence of dystrophin causes Duchenne muscular dystrophy (DMD), characterized by progressive muscle weakness. Much of our knowledge comes from experimental evidence obtained from the mdx mouse, the murine animal model of DMD that also lacks the expression of dystrophin. In mdx mice, elimination of dystrophin expression leads to the absence of the dystrophin-associated glycoprotein complex (DAG), which serves as a membrane anchor. Without DAG, the overall membrane integrity is compromised, leading to impaired Ca^{2+} homeostasis, for example, increased Ca^{2+} influx, activation of Ca^{2+}-dependent proteases and muscle necrosis [2]. However, conflicting data have been reported for both the increase in resting Ca^{2+} concentration ([Ca^{2+}]i) and the amplitude of Ca^{2+} responses upon stimulation [3–5], indicating that the molecular mechanisms of the disease are still unclear. The dysfunction of smooth muscle due to the absence of dystrophin in DMD was earlier suggested [6].

A key aspect of the Ca^{2+} signalling pathway is represented by its spatial and temporal complexity that regulates muscle excitation–contraction coupling. Two well-characterized Ca^{2+} channel complexes
represent the central elements of this excitation–contraction coupling: the voltage-gated \( \text{Ca}^{2+} \) channel (CaV) and the ryanodine-sensitive \( \text{Ca}^{2+} \)-release channel (RYR). In skeletal muscle, CaV and RYR channels interact directly at the triad junction, whereas in cardiac and smooth muscles, a \( \text{Ca}^{2+} \)-induced \( \text{Ca}^{2+} \) release (CICR) mechanism appears to be the dominant process for the release of \( \text{Ca}^{2+} \) from the sarcoplasmic reticulum (SR). In addition, the three RYR sub-types are differentially expressed in muscles, as RYR1 and RYR2 are mainly found in skeletal and cardiac muscles, respectively [7, 8]. In vascular smooth muscle, both RYR1 and RYR2 are required for \( \text{Ca}^{2+} \) release from the SR, although the three RYR sub-types are expressed [9, 10]. The decrease of RYR2 expression in the duodenal muscles of mdx mice was reported [11], but it has been under debate in the case of cardiac myocytes [12, 13]. Finally, the contraction of portal vein in mdx mice is decreased [14].

In mdx mice and in patients with DMD, the absence of dystrophin is due to a point mutation generating a premature stop codon [15]. Aminoglycoside antibiotics, such as gentamycin, have been described to suppress the nonsense mutation in vivo [16]. This family of antibiotics can restore dystrophin function in mdx skeletal muscle [17] and the mechanotransduction and vasodilation in vascular muscle [18]. These results suggest that aminoglycoside treatment is a putative therapeutic approach for DMD [19].

In this study, we investigated the different expression of RYR sub-types in portal vein smooth muscle from mdx mice. We addressed this issue by using RT-PCR and Western blot to evaluate the expression of RYR sub-types in myocytes from wild-type and mdx mice changes in \( \text{Ca}^{2+} \) signals of vascular myocytes by confocal microscopy with Fluo-4. We show for the first time that the RYR2 sub-type expression is selectively impaired in vascular myocytes of mdx mice, and that inhibition of RYR2 expression reduced \( \text{Ca}^{2+} \) release from the SR and spontaneous \( \text{Ca}^{2+} \) sparks, leading to impaired contractile function. Finally, we report that treatment of mdx mice with gentamycin restored both the expression level of RYR2 and the caffeine-induced \( \text{Ca}^{2+} \) response.

**Materials and methods**

**Cell preparation**

The investigation conforms to the European Community and French guiding principles in the care and use of animals (authorization to perform animal experiments: A-93-063-003). Wild-type control (C57Bl10) and mdx mice aged 5–8 months were killed by cervical dislocation. Isolated myocytes were obtained from the portal vein by enzymatic dispersion and maintained in culture [20]. Cells were seeded on glass slides in M199 culture medium containing 10% foetal calf serum, 20 units/ml penicillin and 20 \( \mu \text{g} \)/ml streptomycin. Cells were used for \( \text{Ca}^{2+} \) experiments within 24 hrs. To characterize the function of each RYR sub-type by antisense oligonucleotide strategy, the culture conditions were modified as previously described [21]. (In the results and figures, myocytes isolated from wild-type ‘control’ C57Bl10 and mdx mice are indicated as C57 and mdx, respectively.)

**Microinjection of oligonucleotides**

Sequences of phosphorothioate antisense oligonucleotides (asRYR1-3) used in the present study as well as the method of intranuclear oligonucleotide injection were previously described [9]. The vascular myocytes located in a marked area of glass slides were injected, whereas non-injected cells outside this marked area were used as controls. To control the quality of intranuclear microinjection we used Cy5-tagged antisense oligonucleotides, and to verify the efficiency of RYR sub-type deletion the immunostaining of RYR sub-type was performed on injected cells (data not shown).

**Gentamycin treatment**

The mdx mice were intraperitoneally injected daily with gentamycin (MP Biomedicals Illkirch, France; ref 194530; lot R16139) or saline solution (34 mg/kg per injection in 0.4 ml saline solution [18]). Mice were killed after 14 days of treatment.

**RT-PCR**

Total RNA was extracted from freshly dissociated portal vein myocytes using the RNA preparation kit from Epicentre (Madison, WI, USA) following the instructions of the supplier. The RNA concentration was determined by OD260 with Eppendorf biophotometer (Hamburg, Germany). The RT reaction was performed on 50 ng RNA using Sensiscript RT kit (Qiagen, Courtaboeuf, France). Total RNA was incubated with oligoDT(15) primers at 65°C for 5 min. After a 5-min. cooling time at 4°C, the RT mix was added and the mixture was incubated for 60 min. at 37°C. PCR conditions and primer design were previously detailed [9]. Briefly, PCR was performed with 0.25 \( \mu \)g cDNA, 1.25 units of HotStartTaq DNA polymerase (Qiagen), 1 mmol/l of each primer and 200 \( \mu \)mol of each deoxynucleotide triphosphate, in a final volume of 25 \( \mu \)l. Amplicons were separated by electrophoresis (2% agarose gel) and visualized by Syber green staining. Gels were photographed with EDAS 120 and analyzed with KDS1D 2.0 software (Kodak Digital Science, Paris, France). To determine the relative effect of treatments on RYR expression at the mRNA level, the GAPH amplicon was used as a reference to normalized RYR amplicons. As described in our previous study, PCRs were carried out at different numbers of steps to determine the best number of cycles to quantify amplicons.

**Western blot**

Smooth muscles from the portal vein of C57 and mdx mice treated or not with gentamycin were homogenized in an appropriate volume of SDS 10% supplemented with protease inhibitor cocktail (Sigma, Lyon, France). After centrifugation (10 min., 10,000 \( \times \) g), supernatants were collected and the protein content was measured with a DC protein assay kit (Biorad, Marne la Coquette, France). Equal amounts of protein (50 or 100 \( \mu \)g) from C57, mdx and gentamycin-treated mdx tissues were heated at 95°C for 3 min. in Laemmili-loaded buffer, separated by 4–12% SDS-PAGE (Geba Gels, Interchim, Montlucon, France) and electrically transferred to PVDF.
membranes (70 min., 100 V, 4°C). Non-specific binding was blocked by incubating membrane in phosphate buffer saline/Tween (0.1%) containing 5% non-fat dry milk for 1 hr and blots were incubated (overnight, 4°C) with anti-RyR2 (1:1000), anti-RYR1 (1:1000), anti-RYR3 (1:500), anti-InsP3R3 (1:1000) and anti-dystrophin (1:1000) antibodies. Primary antibodies were detected with a horseradish peroxidase–coupled secondary antibody (Santa Cruz Biotechnology, Heidelberg, Germany) using an enhanced chemoluminescence kit (Amer sham Biosciences, Orsay, France). Photographic films were analyzed with the KDS1D 2.0 software. Each experiment was performed three times.

Ca$^{2+}$ measurements

In experiments using laser scanning confocal microscopy, cells were loaded with a physiological solution containing 4 μmol/l fluo-4-AM (20 min. at 35°C). These cells were washed and allowed to cleave the dye to the active fluo-4 compound for at least 10 min. Images were acquired in the line-scan mode (2 msec per scan) of a Bio-Rad MRC 1024ES with Lasersharp2000 software (Biorad). Briefly, Fluo-4 was excited at 488 nm, and the emitted fluorescence was filtered and measured at 540 ± 30 nm. Images were analyzed with IDL software (RSL) as previously detailed [21]. The fluorescence value of each pixel in the line (F) was divided by the fluorescence value of the same pixel at rest levels (F0); fluorescence signals are thus expressed as pixel-per-pixel fluorescence ratios (F/F0). Amplitudes of the responses are expressed as F/F0, which represents the difference between maximal ratio and ratio at the rest level. An algorithm was developed to characterize Ca$^{2+}$ sparks in the line-scan image by their spatial diffusion (2 μm), amplitude, time to half-decay and upstroke velocity. All variables were measured and compared in control and mdx mice.

To verify that the Ca$^{2+}$ probe has similar fluorescence properties in both control and mdx mice, we performed ratiometric measurements of [Ca$^{2+}$$]_i$ with an indo-1 set-up, as described elsewhere [11]. No difference was measured in both probe loading and resting [Ca$^{2+}$$]_i$ level between myocytes from control and mdx mice (not shown).

Caffeine was applied by pressure ejection from a glass pipette for the period indicated in the figures. All experiments were carried out at 26 ± 1°C.

Solutions

The physiological solution contained (in mM) NaCl 130, KCl 5.6, MgCl$_2$ 1, CaCl$_2$ 2, glucose 11 and HEPES 10, pH 7.4, with NaOH. Caffeine was applied to the recorded cell by pressure ejection for the period indicated in the records.

Chemicals and drugs

Collagenase was obtained from Worthington (Freehold, NJ, USA). M199 medium, streptomycin, penicillin, glutamine and pyruvate were from Invitrogen (Cergy-Pontoise, France). Foetal calf serum was from Biowest (Nuaillé, France). Caffeine was from Merck (Darmstadt, Germany). The anti-RYR1, anti-RYR2, anti-RYR3 and anti-dystrophin–specific antibodies were from Millipore (Molsheim, France). The mouse anti-InsP3R3 antibody was from Transduction Laboratory (BD Bioscience, Le Pont de Claix, France). Fluo 4-acetoxymethylester ( fluo-4-AM) was from Interchim. All other products were from Sigma (St. Louis, MO).

Data analysis

Data are expressed as means ± S.E.M.; n represents the number of cells or experiments as indicated in the legend of the figure. Significance was tested by means of paired Student’s t-test when cells were their own control; otherwise, unpaired test was used. P values <0.05 were considered as significant. To measure the effect of gentamycin treatment, a one-way ANOVA was used in association with Dunnett’s test. P values <0.05 were considered as significant.

Results

RYR sub-types expression in myocytes from mdx mice

Expression of RYR sub-types was first detected with RT-PCR in vascular myocytes. To compare expression levels obtained from independent experiments, we normalized the data by using GAPDH as an internal standard. RYR1, RYR2 and RYR3 mRNAs were detected in isolated portal vein myocytes from control and mdx mice. For 30 and 35 cycles, similar levels of RYR1 and RYR3 mRNAs were observed in control and mdx mice, whereas the expression of RYR2 mRNA was strongly inhibited in mdx portal vein myocytes (Fig. 1). In the same manner, we investigated the expression of InsP3-activated Ca$^{2+}$ release channels (InsP3R) and voltage-dependent Ca$^{2+}$ channels (CaV). Neither expressions of both InsP3R and CaV appeared modified (not shown).

These results were confirmed by Western blots in which 100 μg of total proteins were loaded. The loading control protein has been chosen by its molecular weight in a similar range of RYR. We investigated the expression of InsP3R as revealed by RT-PCR, which indicated that InsP3R3 was the most potentially expressed and it was not modified in mdx mice (not shown). Then, the expression of InsP3R3 was measured in the three experiments pooling five different control and mdx mice, and it did not differ between control and mdx mice. Therefore, InsP3R3 was used as a loading control to normalize the expression of RYR sub-types. In portal vein muscle, the RYR2 protein level was significantly inhibited in mdx mice, whereas the expression of RYR1 and RYR3 was not affected (Fig. 2).

Only the expression of RYR2 was affected in mdx mice, but to verify that the decrease in RYR2 expression may affect the vascular responses of mdx mice, we studied the Ca$^{2+}$ responses in isolated portal vein myocytes.

Caffeine-activated Ca$^{2+}$ signal in mouse portal vein myocytes

Applications of caffeine (10 mmol/l) activated propagation of Ca$^{2+}$ waves in control and mdx myocytes (Fig. 3A). These caffeine-induced Ca$^{2+}$ waves were characterized by their mean amplitude,
time to peak and upstroke velocity. In mdx portal vein myocytes, caffeine-activated Ca\textsuperscript{2+} waves were significantly decreased compared with control myocytes, that is, the peak amplitude and maximal rate of rise were decreased, whereas the time to peak was increased (Fig. 3B). The inhibition of caffeine-activated Ca\textsuperscript{2+} responses by application of 1 \textmu mol/l thapsigargin (n = 9) or 10 \textmu mol/l ryanodine for 30 min. (n = 11) indicates that they depend on Ca\textsuperscript{2+} release from the SR by RYR.

To investigate if the decreased expression of RYR2 may be responsible for the decrease of caffeine-induced Ca\textsuperscript{2+} response, we inhibited RYR2 expression in control myocytes by injecting antisense oligonucleotide directed against the RYR2 sub-type in C57 portal vein myocytes. As previously shown on rat and mouse myocytes [9, 22], (i) the inhibition of one RYR sub-type did not modify the expression of the others and (ii) the maximum inhibitory effect of asRYR on RYR sub-type expression was observed 2–3 days after nuclear injection. After each experiment, the decrease in RYR2 expression induced by asRYR2 treatment was verified by RYR2 immunostaining (not shown). Based on this culture time scale, the caffeine-induced Ca\textsuperscript{2+} responses were measured in myocytes injected with 10 \textmu mol/l asRYR2. Firstly, the culture conditions cannot modify the caffeine-induced Ca\textsuperscript{2+} release (amplitude: 3.30 ± 0.4 ratio units; time to peak: 0.78 ± 0.11 sec; upstroke velocity 15 ± 2 \Delta F/F \cdot s\textsuperscript{-1}). Amplitude, time to peak and upstroke velocity of caffeine-induced Ca\textsuperscript{2+} waves were significantly reduced in asRYR2-injected cells compared with non-injected cells (Fig. 3A and B).

As described previously in rat, caffeine-induced Ca\textsuperscript{2+} responses were totally inhibited by the injection of the cocktail asRYR1 + asRYR2, and similar inhibitions as those obtained in asRYR2-injected cells were obtained in asRYR1-injected cells. In contrast, no inhibitory effect on the Ca\textsuperscript{2+} responses was observed in cells injected with asRYR3. It is noteworthy that injection of scrambled sequences of asRYR1 or asRYR2 had no effect on the caffeine-induced Ca\textsuperscript{2+} waves (Supplementary Information). These results indicate that as described in rat, both RYR1 and RYR2 are required for triggering Ca\textsuperscript{2+} responses in mouse portal vein myocytes [9], and the inhibition of RYR2 was sufficient to significantly inhibit partially caffeine-induced Ca\textsuperscript{2+} response.

The SERCA function was not modified in mdx mice; we applied thapsigargin (1 \textmu M) to follow the Ca\textsuperscript{2+} leak induced by SERCA inhibition. The responses induced by thapsigargin in portal vein myocytes from control and mdx mice were similar.

Fig. 1 Expression of RYRs in portal vein muscle from control and mdx mice. (A) RT-PCR analysis of RYR1, RYR2, RYR3 and GAPDH mRNAs in freshly dissociated portal vein myocytes for 35 cycles. (B) RT-PCR analysis of RYR2 and GAPDH mRNAs for different cycle protocols. (C) Relative mRNA expression levels of the three RYR sub-types were compared with GAPDH expression in control (open bars) and mdx portal vein myocytes (filled bars). Molecular sizes standards are indicated in bp. Data are means ± S.E., with the number of experiments indicated in parentheses. *, values significantly different from those obtained in control mice (P < 0.05).

Fig. 2 Western blotting of RYR sub-types expressed in portal vein muscles. RYR sub-types were revealed in proteins extracted from control and mdx mice. InsP3R3 expression was used as control loading (upper panel). Results from three mdx (filled bars) and control (open bars) preparations were normalized to the loading control (lower panel). Data are means ± S.E. with the number of experiments in parentheses. *, values significantly different from those obtained in control mice (P < 0.05).
Spontaneous Ca$^{2+}$ sparks in mouse portal vein myocytes

RYR2 in association with RYR1 is also needed to encode spontaneous localized Ca$^{2+}$ events (i.e., Ca$^{2+}$ sparks) [9]. In control vascular myocytes, analysis of line-scan fluorescence images revealed spontaneous, spatially localized, Ca$^{2+}$ sparks in about 28% of the cells tested (Fig. 4A). The means of amplitude ($\Delta F/F_0$), time at half decay (s) and upstroke velocity ($\Delta F/F_0 \cdot s^{-1}$) of Ca$^{2+}$ sparks were measured (Fig. 4B). The mean full width at half-maximum amplitude was estimated to 1.05 ± 0.09 μm ($n = 18$; four dissociations were tested). In portal vein myocytes from mdx mice, spontaneous Ca$^{2+}$ sparks were revealed only in 6% of the cells tested (four dissociations were tested). The kinetic variables of these Ca$^{2+}$ sparks were not significantly different from those measured in control myocytes (Fig. 4B). As illustrated in Fig. 4, it has been possible to visualize two different Ca$^{2+}$ spark sites in a control cell, whereas it never happened in mdx myocytes. In asRYR2-treated cells, Ca$^{2+}$ sparks were not observed in the 26 tested cells from three different cell cultures, which indicates that RYR2 was implicated in Ca$^{2+}$ sparks in vascular myocytes.

Taken together, these results confirm that full expression of RYR2 is required for triggering Ca$^{2+}$ sparks and waves in mouse vascular myocytes because inhibition of RYR2 in mdx myocytes inhibited the frequency of Ca$^{2+}$ sparks and reduced caffeine-induced Ca$^{2+}$ responses.

Gentamycin treatment has been shown to increase the expression of full-length dystrophin in mdx muscles. Therefore, we investigated the effect of gentamycin on RYR-dependent Ca$^{2+}$ signalling in portal vein myocytes.

Effect of gentamycin on RYR expression

Gentamycin is an aminoglycoside compound. A property of this molecule family is its ability to shunt stop codon. Here it has been
used to ‘improve’ the aberrant stop codon produced by the mutation observed in mdx mice. The mdx mice were treated by intraperitoneal injection of gentamycin sulphate (gentamycin-treated mdx mice) or injected with saline solution (untreated mdx mice) during 14 days. The duration of the treatment was described to be sufficient to reverse the decrease of vessel contractility observed in mdx mice [18]. Firstly, the efficiency of gentamycin treatment was verified by Western blot analysis of dystrophin expression. Dystrophin was revealed in control mice as well as in gentamycin-treated mdx mice, but dystrophin was not expressed in untreated mdx mice (Fig. 5). Secondly, the effect of gentamycin treatment on the expression of RYR sub-types was measured. From 25 to 35 cycles, the expression of RYR2 was significantly increased in myocytes from gentamycin-treated mdx mice in comparison with untreated mdx mice. The level of RYR2 expression was restored at the same level as was observed in myocytes from control mice (Fig. 6A). The expression of RYR1 was not significantly modified by the gentamycin treatment. The RYR2 sub-type could be negatively regulated by a dominant negative splice variant of RYR3 [23, 24]. The investigation of expression of both dominant negative and full-length RYR3 isoforms was performed by RT-PCR, which indicated that the level of each isoform was not modified by the gentamycin treatment (Fig. 6A). The expression levels of RYR1 and RYR3 were similar in control, gentamycin-treated and untreated mdx mice. The restoration by gentamycin treatment of RYR2 protein level was confirmed by Western blots, in which 100 and 50 μg of total proteins were loaded (Fig. 6B).

**Effect of gentamycin on Ca²⁺ signalling**

The amplitude and upstroke velocity of caffeine-activated Ca²⁺ release were significantly increased in myocytes from gentamycin-treated mdx mice in comparison with untreated mdx mice. It is noticeable that the caffeine-activated Ca²⁺ responses were identical in control C57 mice and in gentamycin-treated mdx mice (Fig. 7A). This last result indicated that the RYR-dependent Ca²⁺ release was restored by gentamycin treatment. The most important role of RYR in smooth muscle is the amplification of InsP3-dependent Ca²⁺ response activated by neurotransmitters; therefore, we investigated the effect of gentamycin on ACh-induced Ca²⁺ response. As illustrated in Fig. 7B, the amplitude of ACh-evoked Ca²⁺ response was significantly reduced in mdx mice in comparison with those observed in control mice. This effect was similar to those observed in cells injected with asRYR2, indicating that the decrease of RYR2 expression was sufficient to decrease the CICR mechanism. The treatment with gentamycin increased the amplitude of the ACh-induced Ca²⁺ response in mdx mouse myocytes to a similar level as that observed in control mice.
We show here that RYR1 and RYR2 are essential for Ca\(^{2+}\)ostasis, but the molecular mechanisms are still poorly understood. The decrease of RYR2 expression observed in mdx mice [14] or the deregulation of vascular function observed in arteries [18, 30]. In theory, the spontaneous Ca\(^{2+}\) sparks could also be blunted by the decrease of Ca\(^{2+}\) sparks frequency. The decrease of RYR2 expression observed in mdx mice caused the same decrease of caffeine-induced Ca\(^{2+}\) response as that observed in asRYR2-injected cells from control mice, indicating that the CICR mechanism was affected in the portal vein, as previously described in duodenum myocytes [11]. In fact, the portal vein displays a spontaneous contractile activity regulated by action potentials. The contraction phase is activated by depolarization owing to CaV channel activation that induces the CICR mechanism. The relaxation is due to the repolarization phase as a result of Ca\(^{2+}\)-dependent K\(^+\) currents, which exert a tonic hyperpolarizing and inhibitory influence on the contraction of vascular myocytes [26, 27]. In the absence of Ca\(^{2+}\) sparks, myocytes should be depolarized and incompletely relaxed, thus limiting contractility. In patients with DMD and mdx mice, the decrease of relaxation of \(\alpha\)-adrenergic-induced contraction was attributed to the decrease of NO muscle production [28, 29]. Our data suggest that the vasoregulation by relaxation could also be blunted by the decrease of Ca\(^{2+}\) sparks frequency.

In patients with Duchenne muscular dystrophy and mdx mice, it is generally accepted that the missing link between the absence of dystrophin and muscle hypotonicity is due to alterations in Ca\(^{2+}\) homeostasis, but the molecular mechanisms are still poorly understood. We show here that RYR1 and RYR2 are essential for Ca\(^{2+}\) signals in mice vascular myocytes and that expression of the RYR2 sub-type is selectively decreased in vascular smooth muscles of mdx mice. In contrast, RYR3 and RYR1 expressions were not affected. In mdx vascular myocytes where RYR2 expression was strongly decreased, the caffeine-induced Ca\(^{2+}\) responses and the frequency of Ca\(^{2+}\) sparks were reduced. The injection of gentamycin in mdx mice led to restoration of both dystrophin and RYR2 expression to the same levels as those observed in control mice. Caffeine-induced Ca\(^{2+}\) response was also rescued by gentamycin treatment.

As previously reported in rat portal vein myocytes [9], both RYR1 and RYR2 are required in mouse portal vein myocytes for triggering caffeine-induced Ca\(^{2+}\) waves and Ca\(^{2+}\) sparks. In the urinary bladder from RYR1-KO mouse, RYR2 and RYR3 are sufficient for encoding spontaneous Ca\(^{2+}\) sparks and caffeine-activated Ca\(^{2+}\) waves, whereas the frequency of depolarization-activated Ca\(^{2+}\) sparks was decreased but the KO of RYR1 was not compensated by RYR2 over-expression [25]. From these data and the present ones, we may postulate that vascular RYR clusters are formed by both RYR1 and RYR2 (as homotetramers), and therefore suppression of either RYR1 or RYR2 decreases the caffeine-induced Ca\(^{2+}\) responses and the frequency of Ca\(^{2+}\) sparks. Interestingly, in mdx vascular myocytes, the reduction of RYR2 expression was also associated with the decrease of frequency of Ca\(^{2+}\) sparks. This observation strengthens the idea that both RYR1 and RYR2 are required for triggering Ca\(^{2+}\) sparks in mouse portal vein myocytes. The potential consequences could be the decrease of vascular tone because Ca\(^{2+}\) sparks activate transient outward K\(^+\) currents, which exert a tonic hyperpolarizing and inhibitory influence on the contraction of vascular myocytes [26, 27].

Discussion

Fig. 7 Effect of gentamycin on caffeine- and ACh-induced Ca\(^{2+}\) responses in mouse portal vein myocytes. (A) Amplitude and upstroke velocity of caffeine-induced Ca\(^{2+}\) responses in vascular myocytes from control (open bars), mdx (filled bars) and gentamycin-treated mdx mice (hatched bars). (B) Amplitude of ACh-induced Ca\(^{2+}\) response in portal vein from control (open bar), mdx (filled bar), gentamycin-treated mdx mice (hatched bar) and asRYR2-injected myocytes (grey bar). The number of cells tested is indicated in parentheses, and cells were obtained from three different batches (★ and ●, P < 0.05). Myocytes were loaded with fluo 4-AM.

In patients with Duchenne muscular dystrophy and mdx mice, the decrease of vascular reactivity observed in portal vein from mdx mice [14] or the deregulation of vascular function observed in arteries [18, 30]. In theory, the spontaneous Ca\(^{2+}\) sparks could be responsible for the relaxation side of the basal vascular tone, but a change in the basal vascular tone was not clearly identified [14]. The contraction could be also activated by agonists. The following of ACh-induced Ca\(^{2+}\) response as that observed in asRYR2-injected cells from control mice, indicating that the CICR mechanism was affected in the portal vein, as previously described in duodenum myocytes [11]. In fact, the portal vein displays a spontaneous contractile activity regulated by action potentials. The contraction phase is activated by depolarization owing to CaV channel activation that induces the CICR mechanism. The relaxation is due to the repolarization phase as a result of Ca\(^{2+}\)-dependent K\(^+\) currents. In mdx mice, the CICR mechanism and activation of Ca\(^{2+}\)-dependent K\(^+\) currents are both affected, and our data suggest that a Ca\(^{2+}\) signalling defect could explain the decrease of spontaneous contraction of portal vein from the mdx mice [14] or the deregulation of vascular function observed in arteries [18, 30]. In theory, the spontaneous Ca\(^{2+}\) sparks could be responsible for the relaxation side of the basal vascular tone, but a change in the basal vascular tone was not clearly identified [14]. The contraction could be also activated by agonists. The following of ACh-induced Ca\(^{2+}\) response indicates that the amplification of Ca\(^{2+}\) signals by the CICR mechanism was decreased in mdx mice. This result also potentially explains the decrease of vascular reactivity observed in portal vein from mdx mice [14] or also vessels [30]. In mdx skeletal muscle, the absence of dystrophin disturbs the plasma membrane architecture that modifies the action potential-induced Ca\(^{2+}\) signal [31, 32]. The resulting increase of resting Ca\(^{2+}\) induced cell proteolysis and cell death [33]. In smooth muscle from mdx mice, the modification of Ca\(^{2+}\) homeostasis induced by the decrease of
RYR2 expression could be interpreted as a vascular tissue adaptation to the fragility because of the absence of dystrophin, as proposed in carotid arteries [30]. The regulation of RYR expression appears as the subtle mechanism to regulate Ca^{2+} signalling in smooth muscle not only in physiological conditions such as during pregnancy [23] but also in specific environmental stimulation such as microgravity [34]. Our results also confirm that the adaptation of mdx vessels as observed in mesenteric arteries appears insensitive to vasodilator agents. Moreover, this study indicates that a functional linkage might exist between dystrophin and RYR in smooth muscle, and the regulation of RYR expression could be an adaptation of smooth muscle physiology. We can speculate that the decrease of CICR via RYR expression is able to limit Ca^{2+}-induced cell death in mdx smooth muscle.

As described in severe cystic fibrosis, the use of aminoglycoside restores CFTR function by overcoming the premature stop codon [36], and clinical assays were performed [37]. However, as reviewed recently [38], the restoration of dystrophin expression in mdx mice by gentamycin was effective in vitro and in vivo, but its use was limited by the nature of mutation and was not efficient for all patients with DMD. The exon-skipping property of gentamycin was proposed to restore dystrophin expression in patients with DMD and in mdx mice [17]. We propose here that in smooth muscle, gentamycin restores the RYR2 expression level and the associated Ca^{2+} signalling. Together with results showing the restoration of NOS expression associated with NO-dependent dilatation [18], our results reinforced that gentamycin treatment could be proposed to patients with DMD. Recently, a study indicated that the restoration of dystrophin, only in vascular smooth muscle, improves aberrant regulation observed in mdx mouse vessels [39]. Our results, obtained in mdx mouse portal vein, prove that the restoration of dystrophin is linked to the improvement of Ca^{2+} signalling by the restoration of RYR2 expression. They also suggest that the RYR2 sub-type could be implicated in the Ca^{2+}-dependent mechanism of relaxation via spontaneous Ca^{2+} sparks, whereas RYR1, by its function in depolarization-activated Ca^{2+} sparks, was more strongly implicated in contraction.

In conclusion, our study suggests that the restoration of dystrophin and RYR2 expression by gentamycin in mdx mice induces the restoration of Ca^{2+} signals implicated in vascular tone.

Acknowledgements

We acknowledge N. Biendon for technical support and Dr. A. Prévot for proofreading. This work was supported by grants from Association Française contre les myopathies (AFM) and Centre National de la Recherche Scientifique (CNRS), France.

Supporting Information

Additional Supporting Information may be found in the online version of this article.

Fig. S1. Effects of asRYR1, asRYR2, asRYR3 and asSCB antisense oligonucleotides on caffeine-induced Ca^{2+} responses in control portal vein myocytes. Typical Ca^{2+} waves obtained from the entire line-scan images induced by 10 mmol/L caffeine in non-injected control cells (A); in cells injected with 10 μmol/L asRYR2 antisense oligonucleotide (B) and in cells injected with 10 μmol/L asRYR1 antisense oligonucleotide (C). Compiled data showing the effects of 10 μmol/L asRYR1, asRYR2, asRYR3 and asSCB (antisense oligonucleotide corresponding to the scramble sequence of asRYR2) on both peak amplitude (D) and upstroke velocity (E) of caffeine-induced Ca^{2+} waves. Data are means ± S.E. in non-injected cells (open bars) and antisense oligonucleotide-injected cells (filled bars) with the number of cells tested in parentheses. Cells were obtained from three different batches. *, values significantly different from those obtained in non-injected cells (p < 0.05). Myocytes were loaded with fluo 4-AM.

This material is available as part of the online article from: http://www.blackwell-synergy.com/doi/abs/10.1111/j.1549-9622.2009.01111.x
(This link will take you to the article abstract).

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

References

1. Gillis JM. Understanding dystrophinopathies: an inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse. J Muscle Res Cell Motil. 1999; 20: 605–25.
2. Turner PR, Westwood T, Regen CM, et al. Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice. Nature. 1988; 335: 735–8.
3. Bakker AJ, Head SI, Williams DA, et al. Ca^{2+} levels in myotubes grown from the skeletal muscle of dystrophic (mdx) and normal mice. J Physiol. 1993; 460: 1–13.
4. Head SI, Williams DA, Stephenson DG. Abnormalities in structure and function of limb skeletal muscle fibres of dystrophic mdx mice. Proc Biol Sci. 1992; 248: 163–9.
5. Rivet-Bastide M, Imbert N, Cognard C, et al. Changes in cytosolic resting ionized calcium level and in calcium transients during in vitro development of normal and Duchenne muscular dystrophy cultured skeletal muscle measured by laser.
cytofluorometry using indo-1. Cell Calcium. 1993; 14: 563–71.
6. Miyatake M, Milek T, Yoshioka K, et al. Possible systemic smooth muscle layer dysfunction due to a deficiency of dystrophin in Duchenne muscular dystrophy. J Neurol Sci. 1989; 93: 11–7.
7. Takeshima H, Iino M, Takekura H, et al. Excitation-contraction uncoupling and muscular degeneration in mice lacking functional skeletal muscle ryanodine-receptor gene. Nature. 1994; 369: 556–9.
8. Takeshima H, Komazaki S, Hirose K, et al. Embryonic lethality and abnormal cardiac myocytes in mice lacking ryanodine receptor type 2. EMBO J. 1998; 17: 3309–16.
9. Coussin F, Macrez N, Morel JL, et al. Requirement of ryanodine receptor subtypes 1 and 2 for Ca\textsuperscript{2+}-induced Ca\textsuperscript{2+} release in vascular myocytes. J Biol Chem. 2000; 275: 9565–603.
10. Mironneau J, Coussin F, Morel JL, et al. Calcium signalling through nucleotide receptor P2\textsubscript{Y}×1 in rat portal vein myocytes. J Physiol. 2001; 536: 339–50.
11. Morel JL, Rakotobaisoa L, Jeyakumar LH, et al. Decreased expression of ryanodine receptors alters calcium-induced calcium release mechanism in mdx myocytes. J Biol Chem. 2004; 279: 21287–93.
12. Rohman MS, Emoto N, Takeshima Y, et al. A novel calcium sparks. Science. 1995; 270: 633–7.
13. Sastry K, Jeyakumar LH, et al. Calcium sparks. Science. 1995; 270: 633–7.
14. Coussin F, Macrez N, Morel JL, et al. Role of RYR3 splice variants in calcium handling in ventricular myocytes. J Physiol. 2001; 536: 339–50.
15. Fritz N, Mironneau J, Macezn M, et al. Acetylcholine-induced Ca\textsuperscript{2+} oscillations are mediated by a Ca\textsuperscript{2+} release channel (ryanodine receptor). J Biol Chem. 1998; 273: 13081–5.
16. Dabrandis F, Morel JL, Sorrentino V, et al. Regulation of calcium signalling by dominant negative splice variant of ryanodine receptor subtype 3 in native smooth muscle cells. Cell Calcium. 2006; 40: 11–21.
17. Dabrandis F, Fritz N, Mironneau J, et al. Role of RYR3 splice variants in calcium signaling in mouse non-pregnant and pregnant myometrium. Am J Physiol Cell Physiol. 2007; 293: C848–54.
18. Dabrandis F, Fritz N, Mironneau J, et al. Smooth muscle tissues express a major dominant negative splice variant of the type 3 Ca\textsuperscript{2+} release channel (ryanodine receptor). J Biol Chem. 2003; 278: 4763–9.
19. Dabrandis F, Fritz N, Mironneau J, et al. Smooth muscle tissues express a major dominant negative splice variant of the type 3 Ca\textsuperscript{2+} release channel (ryanodine receptor). J Biol Chem. 2003; 278: 4763–9.
20. Dabrandis F, Fritz N, Mironneau J, et al. Smooth muscle tissues express a major dominant negative splice variant of the type 3 Ca\textsuperscript{2+} release channel (ryanodine receptor). J Biol Chem. 2003; 278: 4763–9.
21. Dabrandis F, Fritz N, Mironneau J, et al. Smooth muscle tissues express a major dominant negative splice variant of the type 3 Ca\textsuperscript{2+} release channel (ryanodine receptor). J Biol Chem. 2003; 278: 4763–9.
22. Dabrandis F, Fritz N, Mironneau J, et al. Smooth muscle tissues express a major dominant negative splice variant of the type 3 Ca\textsuperscript{2+} release channel (ryanodine receptor). J Biol Chem. 2003; 278: 4763–9.
23. Dabrandis F, Fritz N, Mironneau J, et al. Smooth muscle tissues express a major dominant negative splice variant of the type 3 Ca\textsuperscript{2+} release channel (ryanodine receptor). J Biol Chem. 2003; 278: 4763–9.